share_log

WEED Inc Announces Exit From Colorado Cannabis Marketplace With Sale of Sangre Biosciences 4-Acre Campus & Hilltop Headquarters for $3.1 Million

WEED Inc Announces Exit From Colorado Cannabis Marketplace With Sale of Sangre Biosciences 4-Acre Campus & Hilltop Headquarters for $3.1 Million

WEED Inc宣佈退出科羅拉多大麻市場,以310萬美元的價格出售Sangre Biosciences佔地4英畝的校園和山頂總部
Accesswire ·  2023/11/30 19:00

TUCSON, AZ / ACCESSWIRE / November 30, 2023 / WEED Inc. (OTCQB:BUDZ), ("WEED" or the "Company") a global cannabis & hemp bioresearch company based in the USA, focused on the development and application of cannabis-derived compounds for the treatment of human and animal diseases, to expand into "consumer packaged goods" utilizing our rare Landrace strains including Original Panama Red, Acapulco Gold, Red Bud Colombian & Santa Marta Gold !

亞利桑那州圖森/ACCESSWIRE/2023 年 11 月 30 日/WEED Inc. (OTCQB:BUDZ),(“WEED” 或 “公司”)是一家總部位於美國的全球大麻和大麻生物研究公司,專注於開發和應用用於治療人類和動物疾病的大麻衍生化合物,利用我們的稀有Landrace菌株,包括原巴拿馬紅、阿卡普爾科金、哥倫比亞紅芽和聖瑪爾塔金屬,擴展到 “消費品包裝產品”!

WEED, a leading cannabis company, is pleased to announce its successful exit from the Colorado cannabis marketplace with the sale of Sangre Biosciences' 4-acre campus for $1.8 million and its headquarters for $1.34 million. The proceeds from these sales will be utilized for strategic acquisitions, with a particular focus on Arizona expansion into testing facilities and buildout of a cGMP certified kitchen to produce CPGs under HEMP BioSciences Inc., a wholly owned subsidiary of WEED Inc. based in Tucson, Arizona USA.

領先的大麻公司WEED很高興地宣佈成功退出科羅拉多州的大麻市場,以180萬美元的價格出售了Sangre Biosciences佔地4英畝的園區,並以134萬美元的價格出售了其總部。這些銷售的收益將用於戰略收購,特別側重於在亞利桑那州擴建測試設施,並在總部位於美國亞利桑那州圖森的WEED Inc.的全資子公司HEMP BioSciences Inc. 旗下建造一間經過cGMP認證的廚房,以生產CPG。

Glenn E. Martin, CEO of WEED, expressed his excitement about the company's recent transactions, stating, "With the sale of our Colorado headquarters last year for $1.34 million and our Sangre research center in July 2023 for $1.8 million, we now have additional funds to concentrate on pursuing acquisitions and development of our HEMP BioSciences division. Our goal is to further develop consumer packaging goods (CPGs) and deliver high-quality, premium products to our customers."

WEED首席執行官格倫·馬丁對公司最近的交易表示興奮,他說:“去年以134萬美元的價格出售了我們的科羅拉多州總部,2023年7月以180萬美元的價格出售了我們的桑格雷研究中心,我們現在有額外的資金可以專注於收購和發展我們的大麻生物科學部門。我們的目標是進一步開發消費包裝產品(CPG),爲我們的客戶提供高品質、優質的產品。”

WEED has established a strong presence in the cannabis and bioscience arena, with operations spanning across Israel, Australia, and the USA. With the current market conditions post Covid, the Company recognizes the opportunity to focus on developing exceptional products using our landrace strains. As part of this effort, HEMP BioSciences, a subsidiary of WEED Inc, is currently constructing a "cGMP" certified kitchen in Tucson, Arizona, to facilitate the development of their consumer products division.

WEED已在大麻和生物科學領域建立了強大的影響力,業務遍及以色列、澳大利亞和美國。在Covid之後的當前市場條件下,公司意識到有機會使用我們的地方品種專注於開發卓越的產品。作爲這項工作的一部分,WEED Inc的子公司HEMP BioSciences目前正在亞利桑那州圖森市建造一個 “cGMP” 認證的廚房,以促進其消費品部門的發展。

Mr. Martin, with 50+ years in sector, emphasized the Company's commitment to quality and innovation, stating, "We believe that now is the time to leverage our expertise and resources to create top-tier products that meet the evolving needs of consumers. By investing in our infrastructure and expanding our capabilities, we believe we are well-positioned to lead the market in 2024 and deliver exceptional value to our customers and shareholders alike"

在行業工作了50多年的馬丁先生強調了公司對質量和創新的承諾,他說:“我們相信,現在是利用我們的專業知識和資源來創造滿足消費者不斷變化的需求的頂級產品的時候了。通過投資基礎設施和擴大我們的能力,我們相信我們完全有能力在2024年引領市場,爲我們的客戶和股東創造非凡的價值。”

WEED looks forward to the next phase of its growth in these endeavors and will continue to explore opportunities to expand its footprint in Arizona, awaiting new regulations to expand in the New York marketplace. WEED will maintain its presence in other global markets. WEED Australia Ltd. & The Cannabis Institute of Australia (C.I.A.) now has 7 full years of audited financials under ASIC rules.

WEED期待着在這些努力中進入下一階段的增長,並將繼續探索擴大其在亞利桑那州足跡的機會,等待新的法規在紐約市場上擴張。WEED將繼續保持其在其他全球市場的影響力。根據澳大利亞證券投資委員會的規定,WEED Australia Ltd.和澳大利亞大麻研究所(C.I.A.)現在擁有整整7年的經審計財務狀況。

About WEED Inc:
WEED Inc is a leading cannabis company dedicated to delivering exceptional products and experiences to the cannabis consumer market. With operations spanning Israel, Australia, and the USA, the company focuses on innovation, quality, and sustainability. Through strategic acquisitions and partnerships, WEED Inc aims to shape the future of the cannabis industry.

關於 WEED Inc:
WEED Inc是一家領先的大麻公司,致力於爲大麻消費市場提供卓越的產品和體驗。該公司的業務遍及以色列、澳大利亞和美國,專注於創新、質量和可持續發展。通過戰略收購和合作夥伴關係,WEED Inc旨在塑造大麻行業的未來。

WEED, Inc.'s Subsidiaries past comments:

WEED, Inc. 's 子公司過去的評論:

WEED Israel (Cannabis) Ltd. "After over 4 years of putting human clinical trials and product development on hold due to COVID and now the war, WEED Israel is still poised and anxious to build out our global brands in both pharmaceutical and non-pharmaceutical categories, starting with women's health and veterans' ailments (PTSD) to healthy green alternative medicines" stated Elliot Kwestel, Managing Director of WEED Israel (Cannabis) Ltd. based outside Jerusalem.

Kwestel further commented, "WEED Israel looks to enrich and expand our clinical trials with both THC and Cannabinoid studies to promote healthy living for generations to come."

WEED 以色列(大麻)有限公司 總部位於耶路撒冷以外的WEED Israel(大麻)有限公司董事總經理艾略特·凱斯特爾表示:“由於COVID和現在的戰爭,WEED Israel暫停了4年多的人體臨床試驗和產品開發,但仍有望在藥品和非藥品類別中建立全球品牌,從女性健康和退伍軍人疾病(PTSD)到健康的綠色替代藥物。”

Kestel進一步評論說:“WEED Israel希望通過四氫大麻酚和大麻素研究來豐富和擴大我們的臨床試驗,以促進子孫後代的健康生活。”

WEED Australia Ltd. and The Cannabis Institute of Australia (C.I.A.), our Australian non-profit arm, based in Queensland on the Gold Coast.

Corporate Director Patrick Brodnik stated, "With the new rules out governing cannabis & hemp in Australia and the announcement in February 2021 to allow over-the-counter CBD medicines in pharmacies, now after Covid, timing is perfect to begin our clinical trials in Israel and Australia to bring new curative products to market as we close out COVID mandates this year.

Managing Director Amanda Brunskill-Scott commented "Next year 2024, the future of USA & Australia decriminalizing cannabis and hemp globally will prove to be a giant leap forward for worldwide cannabis legalization."

WEED 澳大利亞有限公司 澳大利亞大麻研究所(C.I.A.), 我們的澳大利亞非營利機構,總部設在黃金海岸的昆士蘭州。

公司董事帕特里克·布羅德尼克表示:“隨着澳大利亞管理大麻和大麻的新規定出臺,以及2021年2月宣佈允許在藥房中使用非處方CBD藥物,現在是繼Covid之後,我們在以色列和澳大利亞開始臨床試驗以將新的治療產品推向市場的時機已經成熟,因爲我們今年即將結束COVID規定。

董事總經理阿曼達·布倫斯基爾-斯科特評論說:“明年2024年,美國和澳大利亞在全球範圍內將大麻和大麻合法化的未來將被證明是全球大麻合法化的巨大飛躍。”

WEED Hong Kong Ltd. Director Nicole Breen agrees, "The pandemic has affected all of us on a worldwide basis. Healing our planet with natural therapies, treatments and eventual "cures" utilizing natures' own Cannabaceae plant with its many properties, both with high tetrahydrocannabinol (THC) and cannabidiol (CBD) compounds, I believe will change the force of medicine forever in the years to come. We look forward to an exciting year end and a Prosperous 2024"

WEED 香港有限公司 董事妮可·布雷恩表示同意:“疫情在全球範圍內影響了我們所有人。我相信,利用自然療法、治療方法和最終的 “治療方法” 來治癒我們的地球,利用大自然自己的大麻科植物及其多種特性,包括高四氫大麻酚(THC)和大麻二酚(CBD)化合物,我相信將在未來幾年內永遠改變醫學的力量。我們期待着激動人心的年終和繁榮的2024年。”

Caution Regarding Cannabis Operations in the United States:
Any Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. While legal in certain states, cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis.

謹慎對待美國的大麻業務:
任何投資者都應注意,美國的大麻行業有嚴格的法律限制和法規。儘管在某些州是合法的,但根據美國《管制物質法》,大麻仍然是附表一藥物,根據美國聯邦法律,除其他外,種植、分發或擁有大麻是非法的。

That all Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation. That Investors should carefully read the risk factors and disclosures contained in our offering circular before making any decision to invest in our company.

根據適用的美國聯邦洗錢立法,所有涉及在美國產生或意圖促進大麻相關商業活動的收益的金融交易均可構成起訴的依據。投資者在做出任何投資我們公司的決定之前,應仔細閱讀我們的發行通告中包含的風險因素和披露信息。

Forward-Looking Information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "potential", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and include statements with respect to any future revenue and profits.

前瞻性信息:
本新聞稿包含適用證券法所指的 “前瞻性信息”。本新聞稿中包含的前瞻性信息可以通過使用 “可能”、“可能”、“將”、“可能”、“預期”、“預期”、“預期”、“相信、“打算”、“計劃”、“預測”、“項目”、“估計”、“展望” 等詞語來識別,幷包括有關任何未來收入和利潤的陳述。

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

前瞻性信息不能保證未來的業績,它是基於管理層根據管理層對趨勢、當前狀況和預期發展的經驗和看法,以及與情況有關的其他因素,包括對當前和未來市場狀況、當前和未來監管環境的假設,以及許可證、批准和許可證的可用性,做出的許多估計和假設。

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct.

儘管公司認爲此類前瞻性信息所依據的預期和假設是合理的,但不應過分依賴前瞻性信息,因爲公司無法保證這些信息會被證明是正確的。

Actual results and developments may differ materially from those contemplated by these statements.

實際結果和發展可能與這些聲明所設想的結果和發展存在重大差異。

Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements in this press release are made as of the date of this release.

前瞻性信息面臨各種風險和不確定性,這些風險和不確定性可能導致實際事件或結果與前瞻性信息中預測的事件或結果存在重大差異。本新聞稿中的聲明截至本新聞稿發佈之日作出。

That the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws for the relevant country.

除非相關國家的適用證券法要求,否則公司不打算或沒有義務更新任何前瞻性信息,無論是由於新信息、未來事件或業績還是其他原因。

Legal Notice:
That the information is provided for convenience only, it is not investment advice and may not be relied upon in considering an investment in WEED, Inc.

法律聲明:
提供這些信息只是爲了方便起見,它不是投資建議,在考慮對WEED, Inc.的投資時可能不可依據。

That No representation or warranty, express or implied, is made as to the accuracy or completeness of any information contained herein, and any investment decision should be based solely on the information contained in the offering circular and related materials, and the investors independent research.

對於此處包含的任何信息的準確性或完整性,不作任何明示或暗示的陳述或保證,任何投資決策都應僅基於發行通告和相關材料中包含的信息以及投資者的獨立研究。

We advise that No representations or warranty, express or implied, is made as to the future performance of any investment in WEED, Inc. or that investors will or are likely to achieve favorable results, will make any profit at all or will be able to avoid incurring a loss on their investment.

我們建議,對於對WEED, Inc.的任何投資的未來表現,不作任何明示或暗示的陳述或保證,或者投資者將或可能取得良好的業績,將獲得任何利潤或能夠避免投資損失。

In addition, all prospective investors are encouraged to consult with their financial, tax, accounting, or other advisors to determine whether an investment in WEED, Inc. is suitable for them.

此外,鼓勵所有潛在投資者諮詢其財務、稅務、會計或其他顧問,以確定對WEED, Inc.的投資是否適合他們。

Media Contact:
Glenn E. Martin, CEO
1-520-818-8582
Glenn@WEEDincUSA.com

媒體聯繫人:
首席執行官 Glenn E. Martin
1-520-818-8582
Glenn@WEEDincUSA.com

SOURCE: WEED, Inc.

來源:WEED, Inc.


View source version on accesswire.com:
在 accesswire.com 上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論